1. Home
  2. About FDA
  3. Performance Data
  4. FDA-TRACK: Agency-wide Program Performance
  5. FDA-TRACK: FDARA Section 902 Inspections Dashboards
  1. FDA-TRACK: Agency-wide Program Performance

FDA-TRACK: FDARA Section 902 Inspections Dashboards

 

Subscribe to FDA-TRACK Updates

 

FDA-TRACK: CDER
FDA-TRACK: Biologics
FDA-TRACK: Medical Devices
FDA-TRACK Home Page

First enacted in 2012 as part of the Food and Drug Administration Safety and Innovation Act (FDASIA), the FDA User Fee Reauthorization Act of 2022, reauthorizes FDA to assess and collect fees for generic drug products from October 2023 through September 2027. GDUFA is designed to speed the delivery of safe and effective generic drugs to the public and improve upon the predictability of the review process.

Section 902 of the FDA Reauthorization Act (FDARA) requires FDA to publish annual reports on inspections of facilities necessary for approval of a drug or a device conducted during the previous fiscal year (the Report). The FDARA Section 902 Inspections Dashboards (FDARA 902 Dashboards) provide a concise, interactive, and visual presentation of data presented in the Report. The FDARA 902 Dashboards are not intended to replace the Report and are to be used as a supplemental tool for viewing the data. 

 

Data Dashboards to be added.

Sign up to receive FDA-TRACK updates

Get regular FDA email updates delivered on this topic to your inbox.
Back to Top